PSC
ALLO icon

Patient Square Capital’s Allogene Therapeutics ALLO Stock Holding History

Patient Square Capital’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.5M Buy
5,050,000
+1,600,000
+46% +$3.51M 1.63% 17
2026
Q1 		$8.42M Sell
3,450,000
-1,513,756
-30% -$3.03M 1.49% 18
2025
Q4 		$6.8M Buy
4,963,756
+1,982,360
+66% +$2.61M 1.46% 15
2025
Q3 		$3.7M Buy
2,981,396
+346,396
+13% +$413K 0.99% 20
2025
Q2 		$2.98M Buy
2,635,000
+266,814
+11% +$355K 1.07% 16
2025
Q1 		$3.46M Buy
2,368,186
+878,277
+59% +$1.66M 1.43% 15
2024
Q4 		$3.17M Buy
+1,489,909
New +$3.67M 1.19% 15

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Patient Square Capital's ALLO Position: Q2 2026 in Review

Patient Square Capital increased its Allogene Therapeutics (ALLO) stake by 46% in Q2 2026, buying an estimated $3.51M and bringing the position to 5,050,000 shares worth $10.5M. The position accounts for 1.63% of the portfolio, ranked #17.

Patient Square Capital first reported a position in ALLO in Q4 2024 and has held it in 7 quarters since. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Patient Square Capital held 5,050,000 shares of Allogene Therapeutics worth $10.5M as of Q2 2026.
  • Patient Square Capital bought 1,600,000 Allogene Therapeutics shares in Q2 2026, an estimated $3.51M.
  • Allogene Therapeutics made up 1.63% of Patient Square Capital's portfolio in Q2 2026, its #17 holding.
  • Patient Square Capital first reported a position in Allogene Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Patient Square Capital's 13F filing for Q2 2026, filed 12 Aug 2026.